Canaccord raised the firm’s price target on Exagen (XGN) to $15 from $11 and keeps a Buy rating on the shares. The firm updated its model ahead of Q3 results noting that the life science tools secot remains challenged amid multiple headwinds including tariffs, funding uncertainty, and China issues.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XGN: